Head-to-head · WeighScore
Fierce Health vs TeleClinic
The verdict
TeleClinic takes it — 60.8/100 to 56.6/100.
TeleClinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleClinic (Teleclinic Holdings LLC) is a US telehealth platform offering physician-prescribed compounded GLP-1 weight-loss medication — semaglutide and tirzepatide — shipped from a licensed 503A…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fierce Health | TeleClinic |
|---|---|---|
| WeighScore | 56.6/100 | 60.8/100 |
| Grade | C | C |
| Scorecard rank | #410 | #313 |
| Semaglutide | $297/mo (3-month plan, compounded) | $199/mo (compounded) |
| Tirzepatide | $497/mo (3-month plan, compounded) | $299/mo (compounded) |
| Coverage | 30 states | 47 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #410 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #313 · C
Strengths
- Names its pharmacy partner — Rush Pharmacy, a licensed 503A compounder — which many compounded-GLP-1 telehealths won't disclose
- LegitScript certified with flat, published monthly pricing, free shipping, and no insurance required
- Broad access: 47 states with US-licensed physicians and transparent cash-pay pricing
Where it loses points
- Compounded semaglutide and tirzepatide only — no brand-name GLP-1 (Wegovy or Zepbound) option
- Headline $139/$219 rates are first-quarter intro prices billed quarterly; ongoing month-to-month is $199/$299
- Not available in California, South Carolina, or New Jersey
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.